Search

Displaying results 2211 - 2220 of 7540 in total
  1. Drug

    Diethylpropion

    go.drugbank.com/drugs/DB00937
    ApprovedIllicitInvestigational

    A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.

  3. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).

  4. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    It is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  5. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862] … [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  6. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other

  7. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder.

  8. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.

  9. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...

  10. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse … This demonstrates meaningful progress in treatment for patients affected by this disease.[L1739]

    Synonyms: Moab, chimeric, SGN-30, to CD30 antigen